Pfizer has a new leader steering its search for obesity drugs. According to Endpoints News, Danna Breen has been promoted to head of obesity discovery at the company, a move first surfaced through a LinkedIn post.
Breen succeeds Kendra Bence in the role. Endpoints News reports that Breen steps up after nearly 14 years at Pfizer, giving the drugmaker an internal, long-tenured hand at the top of one of the industry's most closely watched research areas.
The details available so far are limited to the appointment itself. The source does not spell out Breen's specific mandate, the size of the team, or the state of Pfizer's obesity pipeline, and no financial terms or timelines were provided.
Why it matters: obesity drugs have become one of the pharmaceutical industry's biggest growth stories, and who runs discovery at a company the size of Pfizer signals how seriously it intends to compete for a slice of that market.